Tenax Therapeutics (TENX) Income from Continuing Operations (2010 - 2026)
Tenax Therapeutics (TENX) reported Income from Continuing Operations of 85624000.0 for Q1 2026, down 722.52% on a YoY basis from 13754329.13 in Q1 2025, and down 451.31% sequentially from 15531000.0 in Q4 2025.
Tenax Therapeutics (TENX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Tenax Therapeutics (TENX) has 16 years of Income from Continuing Operations data on file, last reported at 85624000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 722.52% year-over-year to 85624000.0; the trailing twelve-month figure through Mar 2026 stood at 138784000.0 (down 473.17% YoY), and the FY2025 full-year result was 102949000.0, down 73.66% from the prior year.
- Income from Continuing Operations retreated to 85624000.0 in Q1 2026, from 15531000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2689942.0 in Q3 2022 to a low of 85624000.0 in Q1 2026.
- A 5-year average of 10265444.47 and a median of 3798840.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 104.1% in 2022 and slumped 722.52% in 2026, its largest moves.
- Tracing TENX's Income from Continuing Operations over 5 years: stood at 2554624.0 in 2022, then sank by 580.66% to 12278976.0 in 2023, then soared by 48.96% to 6267000.0 in 2024, then plunged by 147.82% to 15531000.0 in 2025, then slumped by 451.31% to 85624000.0 in 2026.
- Business Quant data shows TENX's Income from Continuing Operations at 85624000.0 in Q1 2026, 15531000.0 in Q4 2025, and 26789000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Tenax Therapeutics | 655.78 Mn | 655.78 Mn | - | -85.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.62 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -26.79 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Mar 31, 2025 | -10.41 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -3.58 Mn |
| Mar 31, 2024 | -3.80 Mn |
| Dec 31, 2023 | -12.28 Mn |
| Sep 30, 2023 | 1.95 Mn |
| Jun 30, 2023 | -1.11 Mn |
| Mar 31, 2023 | -1.41 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | -2.72 Mn |
| Dec 31, 2021 | -62.24 Mn |
| Sep 30, 2021 | 3.45 Mn |
| Jun 30, 2021 | 1.84 Mn |